Feb 24, 2022 / 09:30AM GMT
Sigurdur Oli Olafsson - Hikma Pharmaceuticals PLC - CEO & Executive Director
So good morning, everybody. Welcome to the people here in the room. You made it through the weather to visit our office. So it's great to see people face-to-face. And also, welcome to the people on the line.
We are very pleased to talk to you today both from a personal point of view of seeing people face-to-face for the first time in 2 years, but secondly, to talk about the great results that we had in 2021.
I'm not going to go through the results. I think you saw the press release and you have the presentation this morning. A strong growth in all 3 businesses in 2021. A lot of new launches, many business development deals. A challenging environment still in the U.S. But overall, I think the performance was really, really good in all 3 businesses, and a strong guidance for 2022.
So with that, I was just going to open it up for question and answer, and maybe we start in the room here. And then, of course, we go online a little bit later on when we are running out of questions in the room. So who
Full Year 2021 Hikma Pharmaceuticals PLC Earnings Call - Q&A Session Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers